RxDoctor Payments Data

Neil Steinberg, MD

Psychiatry · Independence, OHNPI 1467465781

Payments from drug & device makers

$10,851in general payments, 2019–2025

Across 471 payments — averaging $23.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$2K
  • AbbVie$1K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
  • Lundbeck LLC$907
  • Johnson & Johnson$865
  • Vanda Pharmaceuticals Inc.$721
  • plus $4K from 20 others

What the payments were for

  • Food & beverage$10,818100%
  • Education$320%
  • Gifts$00%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,851 in reported general payments places this provider in the 90th percentile of 1,119 psychiatry providers in Ohio.

See all psychiatry providers in Ohio

Medicare billing

Part B allowed, 2024
$41,007
Medicare patients
66
Services billed
510

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LybalviOlanzapine/Samidorphan Malate11$16,547
TrintellixVortioxetine Hydrobromide15$13,221
Nefazodone Hcl12$4,460
Desvenlafaxine Succinate ErDesvenlafaxine Succinate16$3,307
Quetiapine Fumarate ErQuetiapine Fumarate17$2,827
Bupropion XlBupropion Hcl88$2,158
Venlafaxine Hcl ErVenlafaxine Hcl77$2,119
Sertraline Hcl142$1,473
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine24$1,429
Duloxetine Hcl47$1,191
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine35$826
Clonazepam61$769
Trazodone Hcl89$695
Fluoxetine Hcl81$667
Fluvoxamine Maleate27$648

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Alkermes, Inc.Lybalvi$275$16,54711 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$416$13,22115 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,119 psychiatry providers in Ohio.

Other psychiatry in Independence

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →